Info

Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent - leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. Tryton was founded in 2003 by Aaron V. Kaplan, M.D. (Dartmouth Medical School/Dartmouth Hitchcock Medical Center) and Spray Venture Partners to develop proprietary stent technology to treat branchpoint lesions. Spray Venture Partners is a venture capital firm that has been focused exclusively on early stage medical technology companies since 1996. The Tryton Side-Branch StentÔ is a unique balloon expandable, 5 French compatible system that is delivered with a single wire. When used in conjunction with any existing standard stent for the main vessel, it provides superior coverage and hoop strength to the origin of the sidebranch.